The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
p63 is a cereblon substrate involved in thalidomide teratogenicity
Abstract
Cereblon (CRBN) is a primary target of thalidomide and mediates its multiple pharmacological activities, including teratogenic and antimyeloma activities. CRBN functions as a substrate receptor of the E3 ubiquitin ligase CRL4, whose substrate specificity is modulated by thalidomide and its analogs. Although a number of CRL4 CRBN substrates have recently been identified, the substrate involved in thalidomide teratogenicity is unclear. Here we show that p63 isoforms are thalidomide-dependent CRL4 CRBN neosubstrates that are responsible, at least in part, for its teratogenic effects. The p53 family member p63 is associated with multiple developmental processes. ∆Np63α is essential for limb development, while TAp63α is important for cochlea development and hearing. Using a zebrafish model, we demonstrate that thalidomide exerts its teratogenic effects on pectoral fins and otic vesicles by inducing the degradation of ∆Np63α and TAp63α, respectively. These results may contribute to the invention of new thalidomide analogs lacking teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“thalidomide-induced degradation of SAll4, and to some extent PlZF and p63 (Asatsuma-Okumura et al. 2019;yamanaka et al. 2021), was confirmed as the root cause of the teratogenic deformities affecting thousands of babies (Matyskiela et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Asatsuma-Okumura et al. 2019
In the citing paper
“The subcellular localizations of these factors differ: the transcription factors Ikaros, Aiolos, and MEIS2 are localized to the nucleus, whereas GSPT1, CK1α, and glutamine synthetase reside in the cytoplasm.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [15]
In the citing paper
“To date, over a dozen proteins including Ikaros, Aiolos, GSPT1, CK1α, glutamine synthetase, MEIS2, KCNMA1/SLO1, CLC1, and AMPKα have been identified as substrates for CRBN3,11–16,24–28.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [15]
In the citing paper
“The subcellular localizations of these factors differ: the transcription factors Ikaros, Aiolos, and MEIS2 are localized to the nucleus, whereas GSPT1, CK1α, and glutamine synthetase reside in the cytoplasm.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [15]
Citations
Cites
High-resolution in situ hybridization to whole-mount zebrafish embryos
Thisse, C., & Thisse, B. (2007) · Nature Protocols · doi:10.1038/nprot.2007.514 · Cited by 2,587
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,485
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C. J., Sharpe, A. H., Caput, D., Crum, C. P., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,264
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Self-citationp63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X., Vogel, H. S., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 2,015
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–137 of 137
Zebrafish in Drug Discovery: Safety Assessment
Cassar, S. C. (2022) · Springer eBooks · doi:10.1007/978-3-030-73317-9_85-1 · Cited by 2
Small-molecule degron mimetics for targeted protein degradation
Liu, X. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253026 · Cited by 2
Ito, T., Asatsuma‐Okumura, T., Endo, A., Yamamoto, J., Iwai, Y., Yamaguchi, Y., Naito, M., Handa, H., & Saeki, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3510134/v1 · Cited by 2
Self-citationThalidomide – From a Banned Drug to Molecular Glues, PROTACs, and New Concepts in Drug Discovery
Yamamoto, J., Handa, H., & Yamaguchi, Y. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch24 · Cited by 2
Self-citationMonteonofrio, L., Virdia, I., Pozzi, S., Quadri, R., Amendolare, A., Marzano, F., Braile, M., Sulfaro, V., Paroni, M., Tullo, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02485-x · Cited by 1
Self-citationNaruse, C., Ishibashi, O., Ohgushi, M., Imai, H., Matsuzaki, T., Pan, X., Miyazaki, T., Shidahara, Y., Shirakawa, Y., Sugiyama, F., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112992 · Cited by 1
Cardiovascular manifestations of thalidomide embryopathy
Klein-Weigel, P. F., & Ding-Greiner, C. (2025) · VASA · doi:10.1024/0301-1526/a001208 · Cited by 1
Developmental toxicology profile of the IRAK4 degrader KT-474
Enerson, B. E., Cappon, G. D., Shi, Y., Walther, D. M., Campbell, V., Chen, D., Kuhn, E. W., Massa, V., Ho, C. M. W., Zheng, X., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf170 · Cited by 1
Zhu, J., Yu, X., Wen, C., Zhang, Y., Kuang, X., Sun, N., Tang, S., Xiao, B., Xiao, S., Wang, X. J., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502444r · Cited by 1
Vargesson, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89773-0.00022-9 · Cited by 2
Toxicological Aspects of PROTACs
Pujari, R., & Soni, U. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_10 · Cited by 1
Kato, Y., Inaba, T., Shinke, K., Hiramatsu, N., Horie, T., Sakamoto, T., Hata, Y., Sugihara, E., Takimoto, T., Nagai, N., et al. (2025) · Cells · doi:10.3390/cells14030215 · Cited by 1
History of IMiDs and Protein Degradation as a Pharmacological Modality
Yamamoto, J., Asatsuma‐Okumura, T., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch8 · Cited by 1
Self-citationSato, T., Saito, K., Oyu, T., Tsuda, S., Kurisaki, T., Kajihara, T., & Nagashima, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3565434/v1 · Cited by 1
Self-citationMiddle Molecular and Conjugation Strategies for Development of Bioactive Middle Molecules
Manabe, Y., Shimoyama, A., Kabayama, K., & Fukase, K. (2020) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.78.527
New Activities of CELMoDs, Cereblon E3 Ligase-modulating Drugs
Matyskiela, M. E., Clayton, T., Thompson, J. W., Carroll, C. W., Bateman, L. A., LeBrun, L. A., & Chamberlain, P. P. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00094
Intermolecular interaction-based ubiquitin-proteasome system-targeting drug discovery
Naito, M., & Komatsu, H. (2020) · Folia Pharmacologica Japonica · doi:10.1254/fpj.20070
Redirecting the Cellular Waste Disposal Machinery to Target Transcription
Yu, H. H., & Sakamoto, K. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-78315-0_23
Kudo, K., Tsuyama, N., Nagata, K., Imaoka, T., Iizuka, D., Sugai, M. T., Muramatsu, M., & Sakai, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1731932/v1
Sato, T., Saito, K., Oyu, T., Yamaguchi, K., Osawa, M., Shiko, Y., Kawasaki, Y., Kurisaki, T., Tsuda, S., Kajihara, T., et al. (2026) · PLoS ONE · doi:10.1101/2023.11.10.566506
Self-citationSMALL-MOLECULE DEGRADERS OF IKAROS ZINC FINGER (IKZF) TRANSCRIPTION FACTORS
Holmberg‐Douglas, N., Shunatona, H. P., Kumi, G. K., & Purandare, A. V. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch10
Zebrafish in Drug Discovery: Safety Assessment
Cassar, S. C. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_85
Naruse, C., Ishibashi, O., Ohgushi, M., Imai, H., Matsuzaki, T., Pan, X., Miyazaki, T., Shidahara, Y., Shirakawa, Y., Sugiyama, F., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5084570
Chemoproteomics Approaches for Diverse Modalities
Eberl, H. C., Knecht, S., Queisser, M. A., & Bantscheff, M. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch19
Jingjing, Z., & Song, T. (2025) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000011570
Liu, J., Yi, L.-H., He, Y., Chen, W., Wang, Y., Yang, L., & Wang, L. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114878
Yan, W., Zhang, N., Liu, X., He, Q., Lv, X., Sun, J., Zhuang, L., Zou, Y., Liang, Y., Liang, Y., et al. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112064
Development of Cathepsin B-Responsive GalNAc-PROTACs for Hepatocyte-Targeting Protein Degradation
Peng, Y., Li, T., Liu, D., Li, W., Zhang, Y., Zhao, Y., Jiang, X., Liang, Y., Chen, P., Ma, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02908
Progress of structurally diverse cereblon (CRBN) ligands and their application in PROTAC degraders
Yang, S., Zhang, Y., Song, X., Liu, Q., Fan, D., & Xu, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109968
Phosphoinositides and inositol phosphates as molecular glues
Seaton‐Terry, A., Cutright, A. J., Loi, M. N. C., Martin, J., Gilligan, J. W., Kubina, J. N., Arambula, M. J., Palmu, S. T., Zhou, D., & Blind, R. D. (2026) · FEBS Letters · doi:10.1002/1873-3468.70388
Genetic evidence supports that thalidomide should not be used therapeutically in dogs
Arendt, M. L., & Meadows, J. R. S. (2026) · Veterinary oncology. · doi:10.1186/s44356-026-00067-2
liu, P., li, C., liu, Y., liu, Y., Liu, J., lv, R., zhou, Q., xing, Q., zhu, H., Wen, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10822026/v1
Mary, E. R. C., & Sudandiradoss, C. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103972
BindingDB (2024) · UC San Diego · doi:10.7270/q2x352pq
Metadata
- Authors
- Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., & Handa, H.
- Affiliations
- Tokyo Medical University (JP)
- Tokyo Institute of Technology (JP)
- University of Milan (IT)
- Corresponding author
- Guerrini, Luisa
- Handa, Hiroshi
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2019-10-07
- Volume
- 15
- Issue
- 11
- Pages
- 1077-1084
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2978105110
- Cited by
- 134
- References
- 50
- Citations by year
- 2026: 6 · 2025: 23 · 2024: 14 · 2023: 19 · 2022: 23 · 2021: 24 · 2020: 25
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (15H04288, 17K14996, 17H06112, S1411011)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Keywords
- thalidomide, cereblon, p63, teratogenicity, p53 family, ΔNp63α, TAp63α, limb development, cochlear development, zebrafish, thalidomide analogues
- MeSH terms
- Humans, Membrane Proteins, Substrate Specificity, Teratogens, Thalidomide, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
